Potential prophylactic and therapeutic vaccines for HSV infections

Current Pharmaceutical Design

Volumn 13, Issue 19, 2007, Pages 1965-1973

  Ramachandran, Srividya ^a   Kinchington, Paul R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immune response; Disabled infectious single cycle viruses; HSV DNA; Interferons; Live virus vaccines; Peptide Vaccines

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ALUMINUM SALT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DISABLED INFECTIOUS SINGLE CYCLE VACCINE; DNA VACCINE; EPITOPE; FREUND ADJUVANT; HERPES SIMPLEX VACCINE; INTERFERON; INTERLEUKIN 12; LIGAND EPITOPE ANTIGEN PRESENTATION VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NITRIC OXIDE; PHOSPHORYL LIPID A; PLACEBO; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VACCINE; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS DNA; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECURRENT INFECTION; REVIEW; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS;

EID: 34447275715     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039760     Document Type: Review

References (83)

1. Whitley R. Fields virology. Philadelphia: Lippincott, Williams & Wilkins; 1996.
2. Xu F SJ, Sternberg MA, Johnson RE, Lee FK, Nahmias AJ, MArkowitz LE. Seroprevalance and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002; 185(8): 1019-24.
3. Mueller SN, Jones CM, Chen W, Kawaoka Y, Castrucci MR, Heath WR, et al. The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells. J Virol 2003; 77(4): 2445-51.
4. Sedarati F, Margolis TP, Stevens JG. Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome. Virology 1993; 192(2): 687-91.
5. Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM, Fraser NW. A herpes simplex virus type 1 mutant containing a non-transinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J. Virol 1990; 64(4): 1630-8.
6. Yang L, Voytek CC, Margolis TP. Immunohistochemical analysis of primary sensory neurons latently infected with herpes simplex virus type 1. J Virol 2000; 74(1): 209-17.
7. Kubat NJ, Amelio AL, Giordani NV, Bloom DC. The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription. J Virol 2004; 78(22): 12508-18.
8. Kubat NJ, Tran RK, McAnany P, Bloom DC. Specific histone tail modification and not DNA methylation is a determinant of herpes simplex virus type 1 latent gene expression. J Virol 2004; 78(3): 1139-49.
9. Ahmed M, Lock M, Miller CG, Fraser NW. Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J Virol 2002; 76(2): 717-29.
10. Perng G-C, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000; 287(5457): 1500-3.
11. Gupta A, Gartner JJ, Sethupathy P, Hatzigeorgiou AG, Fraser NW. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature 2006; 442(7098): 82-5.
12. Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci USA 2002; 99(2): 978-83.
13. Khanna K, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003; 18: 593-603.
14. Sawtell NM, Thompson RL. Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J Virol 2004; 78(14): 7784-94.
15. Daheshia M, Kanangat S, Rouse BT. Production of key molecules by ocular neutrophils early after herpetic infection of the cornea. Exp Eye Res 1998; 67(6): 619-24.
16. Kanangat S, Thomas J, Gangappa. S, Babu JS, Rouse BT. Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection. J Immunol 1996; 156(3): 1110-6.
17. Deshpande SP, Kumaraguru U, Rouse BT. Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2000; 2(8): 973-8.
18. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 1997; 71(4): 3138-45.
19. Manickan E, Rouse BT. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. J Virol 1995; 69(12): 8178-9.
20. Blaney JE Jr, Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, Fu T-M, et al. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 1998; 72(12): 9567-74.
21. Wallace ME, Keating R, Heath WR, Carbone FR. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 1999; 73(9): 7619-26.
22. Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol 1996; 70(1): 264-71.
23. Shimeld C, Efstathiou S, Hill T. Tracking the spread of a lacZ-tagged herpes simplex virus type 1 between the eye and the nervous system of the mouse: Comparison of primary and recurrent infection. J Virol 2001; 75(11): 5252-62.
24. Shimeld C, Whiteland JL, Nicholls SM, Grinfeld E, Easty DL, Gao H, et al. Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. J Neuroimmunol 1995; 61(1): 7-16.
25. Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162(5): 2895-905.
26. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. J Exp Med 1997; 185(11): 1969-75.
27. Suvas S, Azkur AK, Rouse BT. Qa-1b and CD94-NKG2a interaction regulate cytolytic activity of herpes simplex virus-specific memory CD8+ T cells in the latently infected trigeminal ganglia. J Immunol 2006; 176(3): 1703-11.
28. Lang A, Nikolich-Zugich J. Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. J Immunol 2005; 174(5): 2919-25.
29. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. CD8+ T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000; 191(9): 1459-66.
30. Shimeld C, Whiteland JL, Williams NA, Easty DL, Hill TJ. Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1. J Gen Virol 1997; 78(12): 3317-25.
31. Wald A, Zeh J, Bamum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124(1): 8-15.
32. Rodriguez A, Power WJ, Neves RA, Foster CS. Recurrence rate of herpetic uveitis in patients on long-term oral acyclovir. Documenta Ophthalmologica 1995; 90(4): 331-40.
33. Kriesel JD, Spruance SL, Prichard M, Parker JN, Kern ER. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192(1): 156-61.
34. Mikloska Z, Cunningham AL. Herpes simplex virus type 1 glyco-proteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79(2): 353-61.
35. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152(6): 2736-41.
36. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77(4): 525-35.
37. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530): 411-5.
38. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 1986; 137(5): 1636-41.
39. Para MF, Baucke RB, Spear PG. Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors. J Virol 1982; 41(1): 129-36.
40. Jerome KR, Fox R, Chen Z, Sears AE, Lee H-y, Corey L. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol 1999; 73(11): 8950-7.
41. Jerome KR, Tait JF, Koelle DM, Corey L. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol 1998; 72(1): 436-41.
42. Mendez-Samperio P HM, Ayala HE. Induction of transforming growth factor-ß1 by herpes simplex virus. J Interferon Cytokine Res 2000; 20: 273-80.
43. Lee YJ, Han Y, Lu HT, Nguyen V, Qin H, Howe PH, et al. TGF-ß suppresses IFN-{gamma} induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997; 158: 2065-75.
44. Duff R, Rapp F. Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2. J Virol 1971; 8(4): 469-77.
45. Duff R, Rapp F. Oncogenic transformation of hamster embryo cells after exposure to inactivated herpes simplex virus type 1. J Virol 1973; 12(2): 209-17.
46. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, et al. Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer. J Natl Cancer Inst 2002; 94(21): 1604-13.
47. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282(4): 331-40.
48. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347(21): 1652-61.
49. Stanberry L. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004; 11(Suppl 3): 161A-9A.
50. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. J Immunol 1988; 140(1): 294-9.
51. Burke RL. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis 1991; 13(Suppl 11): S906-11.
52. Zheng B, Graham FL, Johnson DC, Hanke T, McDermott MR, Prevec L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993; 11(12): 1191-8.
53. Chabalgoity JA, Khan CMA, Nash AA, Hormaeche CE. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 1996; 19(4): 791-801.
54. Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 1999; 17(6): 535-42.
55. Goel N, Rong Q, Zimmerman D, Rosenthal KS. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 2003; 21(27-30): 4410-20.
56. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, BenMohamed L. Th-cytotoxic T-lymphocyte chimeric epitopes extended by N {varepsilon}-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J Virol 2005; 79(24): 15289-301.
57. Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V, BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 2005; 23(7): 873-83.
58. Meignier B, Longneeker R, Roizman B. In vivo behaviour of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-14.
59. Osorio Y, Ghiasi H. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge. J Virol 2005; 79(6): 3297-308.
60. Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol 2003; 77(10): 5774-83.
61. Sin J-I, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73(1): 501-9.
62. Ghiasi H, Wechsler SL, Cai S, Nesburn AB, Hofman FM. The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Immunology 1998; 95(3): 352-9.
63. Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis 1999; 179(5): 1086-93.
64. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995; 105(1): 31-57.
65. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999; 96(12): 6994-8.
66. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178(1): 92-100.
67. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282(5388): 476-80.
68. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996; 93(21): 11414-20.
69. Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 2006; 24(23): 5016-26.
70. Sin J-I, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated. Protective Immunity Against Herpes Simplex Virus-2 Challenge. J Immunol 1999; 162(5): 2912-21.
71. Nesburn AB, Burke RL, Ghiasi H, Slanina S, Bahri S, Wechsler SL. Vaccine therapy for ocular herpes simplex virus (HSV) infection: Periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol 1994; 68(8): 5084-92.
72. Nesburn AB, Slanina S, Burke RL, Ghiasi H, Bahri S, Wechsler SL. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998; 72(10): 7715-21.
73. Richards CM, Case R, Hirst TR, Hill TJ, Williams NA. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J Virol 2003; 77(12): 6692-9.
74. Straus SE, Savarese B, Tigges M, Freifeld AG, Krause PR, Margolis DM, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167(5): 1045-52.
75. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman. P, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176(5): 1129-34.
76. Walker J, Laycock KA, Pepose JS, Leib DA. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice. Vaccine 1998; 16(1): 6-8.
77. Keadle TL, Laycock KA, Morris JL, Leib DA, Morrison LA, Pepose JS, et al. Therapeutic vaccination with vhs- herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J Gen Virol 2002; 83(10): 2361-5.
78. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994; 170(5): 1100-9.
79. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175(1): 16-25.
80. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24(7): 914-20.
81. Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R, Rytik PG, Kanev AN, Jirathitikal V, et al. Therapeutic AIDS vaccines. Curr Pharm Des 2006; 12(16): 2017-30.
82. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des 2005; 11(6): 775-90.
83. Schang LM. Herpes simplex viruses in antiviral drug discovery. Curr Pharm Des 2006; 12(11): 1357-70.